AI summary by TwinMind
Weight Loss Drugs Before Ozempic
Asianometry
29m 11s
Current Obesity Crisis
- 2022 CDC data: 42% of Americans classified as obese (BMI >30)
- Obesity responsible for up to 14 years lost life expectancy
- Primarily through cardiovascular disease
- US spends nearly $200 billion annually treating obesity-related diseases
- Costs projected to rise in near future
Weight Loss Treatment Approaches
- Lifestyle/behavior changes: easiest but often ineffective for lasting weight loss
- Bariatric surgery: most effective but carries surgical complications
- Pharmacology: intermediate option with troubled history
Three Drug Mechanisms
- Appetite suppression: modifying neurotransmitter release/reabsorption in brain
- Increased energy expenditure: raising metabolism (e.g., caffeine, ephedrine)
- Digestive interference: blocking fat absorption from food
Ancient and Early Treatments
- Second century Greek doctor Siranis of Ephesus: prescribed exercise, heat, massage, laxatives, purgatives
- Roman doctors: recommended vomiting with vinegar, salt water, half cup hyssop plant
- 956 AD: Sancho the Fat (King of Leon) treated with teresia fairacia
- 64 ingredients including opium, ginger, cinnamon, saffron, castor oil
- Successfully lost weight, retook throne
Early Scientific Era (1880s-1930s)
- Late 19th century: industrialization created demand for weight loss drugs
- Thyroid extract treatment:
- Doctors noticed hypothyroidism caused weight gain
- Sheep-derived thyroid extracts reversed symptoms including weight
- Early 1890s: clinical reports on thyroid hormone for obesity
- Drawbacks: abnormal heart rhythm, dangerously high heart rate, possible heart failure
Quack Medicine Era
- Turn of century: proliferation of fake medicines claiming miracle cures
- Names: Allen's Anti-Fat, Frank J Kellogg's Fat Reducer, Marmola, Newman's Obesity Cure, Dr Gordon's Elegant Pill
- Common ingredients: thyroid extract, vomiting agents, appetite suppressants, stimulants
- 1906 Pure Food and Drug Act: limited FDA authority
- 1911 US v. Johnson: Supreme Court ruled act only covered ingredient claims, not therapeutic effects
- 1912 Sherley Amendment: banned misbranding but required proving fraud, not just falsehood
- Created 50-year loophole hampering FDA enforcement
DNP Era (1933-1937)
- Dr Maurice Tainter at Stanford reported 2-4 dinitrophenol (DNP) weight loss properties
- DNP also used for explosives, dye, wood preservative, herbicide
- Discovery: French WWI soldiers/factory workers grew thin after DNP exposure
- Dosage: 3-5 mg/kg initial weight daily = 1.5 kg weight loss per week
- Mechanism: disrupts mitochondrial ATP production, wastes energy as heat
- Risks: hyperthermia, tachycardia, fatal intoxication, cataracts
- Usage: Stanford applied 1.2 million capsules to patients, 100,000+ people took them
- 1935: FDA issued concern but lacked regulatory authority
- 1937 Elixir Sulfanilamide crisis: 100 children died from antifreeze additive
- 1938 Federal Food Drug and Cosmetic Act: gave FDA authority
- FDA removed DNP after 2,500 cataract reports
- Resurfaced in 1980s Texas, still sold online for bodybuilders
Amphetamine Era (1930s-1960s)
- Mechanism: rapid dopamine release, energy rush, increased metabolic rate
- 1933: Smith Klein & French sold Benzedrine as decongestant
- 1935: UC San Francisco study for narcolepsy noted weight loss
- 1947: FDA approved methamphetamine (dysoxy ephedrine) for obesity
- 3 daily doses of 2mg could lose up to 25kg
- Major problem: highly addictive
Rainbow Pills (1941-1968)
- Clark and Clark produced diet pills: amphetamine sulfate + thyroid hormone
- Called "Clark attacks" but branded as "rainbow pills" due to colors
- Sold directly to physicians, bypassing pharmacies
- 1967: 5,000 doctors, 2,000 practices earning $250M fees + $125M pills
- Legal but acknowledged as low ethics
- FDA struggled with action due to:
- Loopholes in 1938 act
- Ingredients already approved for other uses
- Little evidence of harm
- Hesitancy to interfere with medical practice
- Industry money and aggressive marketing
- 1968 Life magazine investigation: reporter got 1,500 pills from 10 clinics
- Senate subcommittee: identified 60+ deaths from rainbow pills
- January 1968: FDA seized 43 million tablets from dozen manufacturers
- 1970s: FDA reconsidered amphetamines for weight loss entirely
Amphetamine Congeners (1950s-1970s)
- Goal: create similar effects without addictiveness
- Phenometrazine (Preludin): approved 1956, eventually found addictive, caused delusions/paranoia
- Phentermine: approved 1959, became exception that survived
- 2019: 3 million prescriptions, 75% US anti-obesity market share
- Cheap generic, works first 12 weeks only
- Long-term complications: palpitations, tachycardia
Fen-Phen Era (1970s-1997)
Background
- Aminorex (1960s): developed by McNeil, sold in Germany/Austria/Switzerland
- Caused 10x increase in primary pulmonary hypertension (PPH)
- PPH: rare condition (1-2 per million), lung blood vessel narrowing, can be fatal
- Swiss study: 71 hospitalized, 34 died
- Drug pulled 1972, epidemic ended
Fenfluramine Development
- 1973: fenfluramine hit market as amphetamine congener
- Different mechanism: releases serotonin, increases fullness, suppresses appetite
- Non-addictive, didn't affect motor activity
- 1981: first PPH reports with fenfluramine
- Problem: didn't work well alone, weight regain occurred
Fen-Phen Combination
- 1979: Dr Michael Weintraub (University of Rochester) combined fenfluramine + phentermine
- 28-week pilot study: combination worked "fantastically"
- Fewer side effects than single drugs
- NIH longer study: week 34 patients lost 15.9% initial weight (14kg/30lbs) vs 4.9% placebo
- 1992: Clinical Pharmacology and Therapeutics published study
- Fen-phen went viral, patients demanded prescriptions
Prescription Explosion
- Phentermine: 1M prescriptions (1991) → 2.3M (1995) → 5M (1996)
- Fenfluramine: 100K prescriptions (1994) → 800K (1995) → 3.8M (1996)
- Entire practices devoted to dispensing fen-phen
Dexfenfluramine Approval
- Companies wanted more specific variant: dexfenfluramine
- September 1995 FDA vote: aware of PPH connection (10x risk increase)
- Initial vote: 5-3 rejection
- Second vote after impassioned plea: 6-5 approval
- April 1996: FDA approval with cautionary warnings (ignored)
- June 1996: hit shelves as "Redux" with massive advertising
- 5 months: 1.2 million prescriptions
Heart Valve Discovery
- December 1994: two echocardiography technicians in Fargo, ND noticed heart valve abnormalities
- Tracked over 2 years: rare but always connected to fen-phen
- February 1997: Mayo Clinic collaboration
- Mechanism: fenfluramine stimulates serotonin receptors on heart valves
- Stimulates protein growth on valve leaflets
- Makes valves thick and leaky
- Causes blood regurgitation, cardiac damage
- June 1997: New England Journal of Medicine accepted article (24 cases)
- July 1997: joint press release by journal, Mayo Clinic, FDA
- September 1997: American Home Products pulled from market
- 9,000 lawsuits filed, $3.75 billion settlement
Recent Failures (2000s-2010s)
Rimonabant (2006-2009)
- Developed by Sanofi-Aventis to block cannabinoid receptors (opposite of marijuana munchies)
- Rat studies: 21% weight loss
- 2-year human trial: 8.6kg loss vs 2-3kg placebo (net 5-6kg)
- Europe approved as "Acomplia"
- US FDA rejected due to depressive disorders in 10% of patients
- 1% had serious self-harm thoughts
- Withdrawn from Europe 2009
Sibutramine (1980s-2010)
- Originally developed by Boots Pharmaceutical UK for depression
- 1988: noticed weight loss in trials
- Mechanism: blocks reabsorption of norepinephrine, serotonin, dopamine
- Results: 12% weight loss after 6 months
- Side effects: higher blood pressure, heart rate
- 1997: US FDA approved
- 2003-2005: Scout study with 10,000+ obese individuals
- Results: 11.4% cardiovascular complications vs 10% placebo
- October 2010: pulled from market
Current State and Future
- Growing obesity epidemic needs solutions
- Century+ history of weight loss drugs full of setbacks
- Pattern: incredible hype → withdrawal after problems discovered years later
- Current drugs have modest effects: 4-6kg additional loss vs placebo over 6-12 months
- Patients have unrealistic expectations, leading to discontinuation
- New category: GLP-1 agonists (glucagon-like peptide 1) seem promising
- History suggests caution despite apparent breakthroughs
